Revenue and Profit - The company's revenue for Q3 2021 reached ¥800,352,256.80, representing a 20.63% increase year-over-year[4] - Net profit attributable to shareholders was ¥27,334,089.51, a decrease of 29.08% compared to the same period last year[4] - The net profit excluding non-recurring gains and losses was ¥16,863,703.00, down 52.32% year-over-year[4] - The net profit attributable to shareholders of the parent company decreased by 42.06% to ¥120,339,441.14 compared to ¥207,683,729.50 in the same period last year, primarily due to increased costs from rising raw material prices and declining market prices in the pharmaceutical intermediate sector[2] - Net profit for the current period was ¥129,756,225.21, a decrease of 39.0% from ¥212,645,545.78 in the previous period[33] - The total comprehensive income for the current period was ¥134,999,223.02, down from ¥212,645,545.78, a decrease of 36.5%[36] Cash Flow - Cash flow from operating activities for the year-to-date was ¥232,213,332.77, reflecting a decline of 47.13% compared to the previous year[4] - The net cash flow from operating activities decreased by 47.13% to ¥232,213,332.77, primarily due to increased procurement expenses and other cash payments related to operating activities[2] - The net cash flow from operating activities was 439.25 million in the previous period[40] - Cash outflow from operating activities totaled 1.45 billion year-over-year[40] - The net cash flow from investing activities was -199.95 million in the previous period[40] Assets and Liabilities - Total assets as of September 30, 2021, amounted to ¥5,148,164,473.55, an increase of 2.96% from the end of the previous year[4] - The company's total assets reached CNY 5,148,164,473.55, up from CNY 5,000,113,119.10 at the end of 2020, indicating an increase of about 2.96%[28] - Total liabilities increased to CNY 1,700,120,234.27 from CNY 1,532,815,590.71, representing a rise of approximately 10.9%[26] - The company's total liabilities amounted to 255.39 million, unchanged from the previous period[46] Share Repurchase and Minority Interests - The company repurchased shares amounting to ¥120,013,694.64, reflecting a 63.17% increase in treasury stock[2] - Minority interests increased by 89.79% to ¥9,416,784.07, driven by profit growth in the company's controlling subsidiaries[2] Fair Value Changes and Special Reserves - The company recorded a fair value change income of ¥5,400,300.00, resulting from the impact of exchange rate fluctuations on foreign currency receivables[2] - The company’s special reserves increased by 962.23% to ¥3,308,756.89 due to higher provisions during the reporting period[2] Accounting Standards and Audit Status - The company adopted the revised Accounting Standards for Leases from January 1, 2021, impacting the recognition of lease liabilities[50] - The third quarter report was not audited, indicating preliminary financial data[51]
金城医药(300233) - 2021 Q3 - 季度财报